Compare JACK & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JACK | LCTX |
|---|---|---|
| Founded | 1951 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.2M | 366.2M |
| IPO Year | 1987 | N/A |
| Metric | JACK | LCTX |
|---|---|---|
| Price | $22.16 | $1.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 3 |
| Target Price | ★ $24.56 | $4.67 |
| AVG Volume (30 Days) | 496.2K | ★ 1.1M |
| Earning Date | 02-18-2026 | 03-09-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,465,314,000.00 | $10,816,000.00 |
| Revenue This Year | N/A | $6.32 |
| Revenue Next Year | N/A | $124.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.05 |
| 52 Week Low | $13.99 | $0.37 |
| 52 Week High | $44.15 | $2.09 |
| Indicator | JACK | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 55.70 |
| Support Level | $20.14 | $1.45 |
| Resistance Level | $21.38 | $1.71 |
| Average True Range (ATR) | 1.11 | 0.09 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 54.30 | 82.83 |
Jack In The Box Inc operates quick-service restaurants and fast-casual restaurants across various states in the United States of America. Its core business includes the Jack in the Box hamburger chain, known for a broad menu that features hamburgers, tacos, sandwiches, salads, and breakfast items. The company also operates the Del Taco brand, which offers a variety of both Mexican and American favorites such as burritos and fries. These foods are available with the option of customization as per customer requirements. The company also offers catering and delivery services to its customers. Jack in the Box and Del Taco restaurant brands are the two reportable operating segments, of which, Jack in the Box generates maximum revenue for the company.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.